Yuyu Pharma Inc (000225) - Net Assets
Based on the latest financial reports, Yuyu Pharma Inc (000225) has net assets worth ₩142.56 Billion KRW (≈ $96.61 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩207.28 Billion ≈ $140.47 Million USD) and total liabilities (₩64.72 Billion ≈ $43.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Yuyu Pharma Inc total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩142.56 Billion |
| % of Total Assets | 68.77% |
| Annual Growth Rate | 6.34% |
| 5-Year Change | 9.22% |
| 10-Year Change | 79.51% |
| Growth Volatility | 8.43 |
Yuyu Pharma Inc - Net Assets Trend (2014–2025)
This chart illustrates how Yuyu Pharma Inc's net assets have evolved over time, based on quarterly financial data. Check 000225 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Yuyu Pharma Inc (2014–2025)
The table below shows the annual net assets of Yuyu Pharma Inc from 2014 to 2025. For live valuation and market cap data, see how much is Yuyu Pharma Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩140.54 Billion ≈ $95.24 Million |
+4.06% |
| 2024-12-31 | ₩135.06 Billion ≈ $91.53 Million |
+12.22% |
| 2023-12-31 | ₩120.36 Billion ≈ $81.56 Million |
-2.45% |
| 2022-12-31 | ₩123.37 Billion ≈ $83.61 Million |
-4.13% |
| 2021-12-31 | ₩128.69 Billion ≈ $87.21 Million |
+9.95% |
| 2020-12-31 | ₩117.04 Billion ≈ $79.31 Million |
+29.26% |
| 2019-12-31 | ₩90.54 Billion ≈ $61.36 Million |
+4.23% |
| 2018-12-31 | ₩86.87 Billion ≈ $58.87 Million |
+4.88% |
| 2017-12-31 | ₩82.83 Billion ≈ $56.14 Million |
+5.80% |
| 2016-12-31 | ₩78.29 Billion ≈ $53.06 Million |
+6.19% |
| 2015-12-31 | ₩73.73 Billion ≈ $49.97 Million |
+3.14% |
| 2014-12-31 | ₩71.49 Billion ≈ $48.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yuyu Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩32.50 Billion | 25.07% |
| Other Components | ₩97.13 Billion | 74.93% |
| Total Equity | ₩129.63 Billion | 100.00% |
Yuyu Pharma Inc Competitors by Market Cap
The table below lists competitors of Yuyu Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TCS Group Holdings Bhd
KLSE:0221
|
$14.10 Million |
|
Euromedis Groupe SA
PA:ALEMG
|
$14.11 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
$14.11 Million |
|
Bina Darulaman Bhd
KLSE:6173
|
$14.11 Million |
|
Gigasun AB
ST:GIGA
|
$14.10 Million |
|
First Media Tbk
JK:KBLV
|
$14.09 Million |
|
Xintela AB
ST:XINT
|
$14.08 Million |
|
BALAXI PHARMACEUTICALS LIMITED
NSE:BALAXI
|
$14.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yuyu Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 125,231,958,120 to 129,631,396,230, a change of 4,399,438,110 (3.5%).
- Net income of 8,154,030,100 contributed positively to equity growth.
- Dividend payments of 1,929,054,100 reduced retained earnings.
- Share repurchases of 1,997,724,540 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩8.15 Billion | +6.29% |
| Dividends Paid | ₩1.93 Billion | -1.49% |
| Share Repurchases | ₩2.00 Billion | -1.54% |
| Other Changes | ₩172.19 Million | +0.13% |
| Total Change | ₩- | 3.51% |
Book Value vs Market Value Analysis
This analysis compares Yuyu Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.26x to 0.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩13510.11 | ₩3550.00 | x |
| 2017-12-31 | ₩6921.45 | ₩3550.00 | x |
| 2018-12-31 | ₩7320.57 | ₩3550.00 | x |
| 2019-12-31 | ₩7543.57 | ₩3550.00 | x |
| 2020-12-31 | ₩7666.18 | ₩3550.00 | x |
| 2021-12-31 | ₩7461.74 | ₩3550.00 | x |
| 2022-12-31 | ₩7144.32 | ₩3550.00 | x |
| 2023-12-31 | ₩6932.58 | ₩3550.00 | x |
| 2024-12-31 | ₩7738.64 | ₩3550.00 | x |
| 2025-12-31 | ₩8231.89 | ₩3550.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yuyu Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.29%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.79%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.60x
- Recent ROE (6.29%) is above the historical average (1.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -10.80% | -11.89% | 0.62x | 1.47x | ₩-14.38 Billion |
| 2015 | -0.35% | -0.36% | 0.67x | 1.46x | ₩-7.41 Billion |
| 2016 | 7.63% | 8.22% | 0.64x | 1.44x | ₩-1.83 Billion |
| 2017 | 5.54% | 7.23% | 0.52x | 1.48x | ₩-3.65 Billion |
| 2018 | 4.69% | 4.84% | 0.61x | 1.58x | ₩-4.56 Billion |
| 2019 | 5.32% | 5.20% | 0.66x | 1.55x | ₩-4.15 Billion |
| 2020 | 1.12% | 1.31% | 0.63x | 1.35x | ₩-10.15 Billion |
| 2021 | -1.78% | -1.91% | 0.60x | 1.55x | ₩-14.64 Billion |
| 2022 | -5.13% | -4.31% | 0.71x | 1.67x | ₩-17.67 Billion |
| 2023 | -6.40% | -5.23% | 0.69x | 1.77x | ₩-18.40 Billion |
| 2024 | 6.96% | 6.55% | 0.64x | 1.66x | ₩-3.80 Billion |
| 2025 | 6.29% | 5.79% | 0.68x | 1.60x | ₩-4.81 Billion |
Industry Comparison
This section compares Yuyu Pharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $393,988,544,527
- Average return on equity (ROE) among peers: 4.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yuyu Pharma Inc (000225) | ₩142.56 Billion | -10.80% | 0.45x | $14.10 Million |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $93.83 Million |
| Yuhan Corp. (000100) | $519.03 Billion | 9.81% | 0.47x | $3.47 Billion |
| Yuhan Corp Preferred (000105) | $1.85 Trillion | 10.44% | 0.30x | $45.29 Million |
| Yuyu Pharma (000220) | $123.37 Billion | -4.85% | 0.58x | $39.92 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $32.17 Million |
| Ildong Holdings Co Ltd (000230) | $172.99 Billion | 13.36% | 0.64x | $45.46 Million |
| Samil Pharm (000520) | $63.55 Billion | 2.11% | 2.02x | $89.63 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $344.25 Million |
| Jw Pharmac (001060) | $119.39 Billion | 10.54% | 2.83x | $362.17 Million |
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more